Association of probiotic use with nivolumab effectiveness against various cancers: A multicenter retrospective cohort study
Abstract Background Previous studies have revealed an association between probiotic use and effectiveness of immune checkpoint inhibitors in renal and lung cancers. However, little is known regarding other cancers, including gastrointestinal cancer. Methods To address this issue, we conducted a mult...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.6313 |
| _version_ | 1827307646529568768 |
|---|---|
| author | Junya Arai Ryota Niikura Yoku Hayakawa Nobumi Suzuki Tetsuro Honda Takuma Okamura Kenkei Hasatani Naohiro Yoshida Tsutomu Nishida Tetsuya Sumiyoshi Shu Kiyotoki Takashi Ikeya Masahiro Arai Narikazu Boku Mitsuhiro Fujishiro |
| author_facet | Junya Arai Ryota Niikura Yoku Hayakawa Nobumi Suzuki Tetsuro Honda Takuma Okamura Kenkei Hasatani Naohiro Yoshida Tsutomu Nishida Tetsuya Sumiyoshi Shu Kiyotoki Takashi Ikeya Masahiro Arai Narikazu Boku Mitsuhiro Fujishiro |
| author_sort | Junya Arai |
| collection | DOAJ |
| description | Abstract Background Previous studies have revealed an association between probiotic use and effectiveness of immune checkpoint inhibitors in renal and lung cancers. However, little is known regarding other cancers, including gastrointestinal cancer. Methods To address this issue, we conducted a multicenter retrospective cohort study and the duration of nivolumab treatment for various cancers was compared between probiotic users and non‐users. Results and Conclusions In total, 488 patients who received nivolumab therapy were included. In all cancers, no significant differences in treatment duration of nivolumab were observed between probiotic users and non‐users (median 62.0 vs. 56.0, hazard ratio = 1.02, p = 0.825), whereas probiotic use, compared with non‐use, in patients with gastric cancer was significantly associated with a longer duration of nivolumab treatment (55.0 vs. 31.0 days, hazard ratio = 0.69, p = 0.039). In conclusion, probiotics may improve the response to nivolumab and potentially prolong progression‐free survival in patients with gastric cancer. |
| first_indexed | 2024-03-12T00:55:08Z |
| format | Article |
| id | doaj.art-5b861f1dea5f4efa9cd3ed1ef3e10e4a |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-24T18:43:08Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-5b861f1dea5f4efa9cd3ed1ef3e10e4a2024-03-27T09:11:00ZengWileyCancer Medicine2045-76342023-08-011216168761688010.1002/cam4.6313Association of probiotic use with nivolumab effectiveness against various cancers: A multicenter retrospective cohort studyJunya Arai0Ryota Niikura1Yoku Hayakawa2Nobumi Suzuki3Tetsuro Honda4Takuma Okamura5Kenkei Hasatani6Naohiro Yoshida7Tsutomu Nishida8Tetsuya Sumiyoshi9Shu Kiyotoki10Takashi Ikeya11Masahiro Arai12Narikazu Boku13Mitsuhiro Fujishiro14Department of Gastroenterology, Graduate School of Medicine The University of Tokyo Tokyo JapanGastroenterological Endoscopy Tokyo Medical University Tokyo JapanDepartment of Gastroenterology, Graduate School of Medicine The University of Tokyo Tokyo JapanDepartment of Gastroenterology, Graduate School of Medicine The University of Tokyo Tokyo JapanDepartment of Gastroenterology Nagasaki Harbor Medical Center Nagasaki JapanDepartment of Gastroenterology Nagasaki Harbor Medical Center Nagasaki JapanDepartment of Gastroenterology Fukui Prefectural Hospital Fukui JapanDepartment of Gastroenterology Ishikawa Prefectural Central Hospital Kanazawa‐shi Ishikawa JapanDepartment of Gastroenterology Toyonaka Municipal Hospital Osaka JapanDepartment of Gastroenterology Tonan Hospital Sapporo‐shi Hokkaido JapanDepartment of Gastroenterology Shuto General Hospital Yamaguchi JapanDepartment of Gastroenterology St. Luke's International Hospital Tokyo JapanDepartment of Gastroenterology Nerima Hikarigaoka Hospital Tokyo JapanDepartment of Gastroenterology, Graduate School of Medicine The University of Tokyo Tokyo JapanDepartment of Gastroenterology, Graduate School of Medicine The University of Tokyo Tokyo JapanAbstract Background Previous studies have revealed an association between probiotic use and effectiveness of immune checkpoint inhibitors in renal and lung cancers. However, little is known regarding other cancers, including gastrointestinal cancer. Methods To address this issue, we conducted a multicenter retrospective cohort study and the duration of nivolumab treatment for various cancers was compared between probiotic users and non‐users. Results and Conclusions In total, 488 patients who received nivolumab therapy were included. In all cancers, no significant differences in treatment duration of nivolumab were observed between probiotic users and non‐users (median 62.0 vs. 56.0, hazard ratio = 1.02, p = 0.825), whereas probiotic use, compared with non‐use, in patients with gastric cancer was significantly associated with a longer duration of nivolumab treatment (55.0 vs. 31.0 days, hazard ratio = 0.69, p = 0.039). In conclusion, probiotics may improve the response to nivolumab and potentially prolong progression‐free survival in patients with gastric cancer.https://doi.org/10.1002/cam4.6313CBM588gastric cancernivolumabprobiotics |
| spellingShingle | Junya Arai Ryota Niikura Yoku Hayakawa Nobumi Suzuki Tetsuro Honda Takuma Okamura Kenkei Hasatani Naohiro Yoshida Tsutomu Nishida Tetsuya Sumiyoshi Shu Kiyotoki Takashi Ikeya Masahiro Arai Narikazu Boku Mitsuhiro Fujishiro Association of probiotic use with nivolumab effectiveness against various cancers: A multicenter retrospective cohort study Cancer Medicine CBM588 gastric cancer nivolumab probiotics |
| title | Association of probiotic use with nivolumab effectiveness against various cancers: A multicenter retrospective cohort study |
| title_full | Association of probiotic use with nivolumab effectiveness against various cancers: A multicenter retrospective cohort study |
| title_fullStr | Association of probiotic use with nivolumab effectiveness against various cancers: A multicenter retrospective cohort study |
| title_full_unstemmed | Association of probiotic use with nivolumab effectiveness against various cancers: A multicenter retrospective cohort study |
| title_short | Association of probiotic use with nivolumab effectiveness against various cancers: A multicenter retrospective cohort study |
| title_sort | association of probiotic use with nivolumab effectiveness against various cancers a multicenter retrospective cohort study |
| topic | CBM588 gastric cancer nivolumab probiotics |
| url | https://doi.org/10.1002/cam4.6313 |
| work_keys_str_mv | AT junyaarai associationofprobioticusewithnivolumabeffectivenessagainstvariouscancersamulticenterretrospectivecohortstudy AT ryotaniikura associationofprobioticusewithnivolumabeffectivenessagainstvariouscancersamulticenterretrospectivecohortstudy AT yokuhayakawa associationofprobioticusewithnivolumabeffectivenessagainstvariouscancersamulticenterretrospectivecohortstudy AT nobumisuzuki associationofprobioticusewithnivolumabeffectivenessagainstvariouscancersamulticenterretrospectivecohortstudy AT tetsurohonda associationofprobioticusewithnivolumabeffectivenessagainstvariouscancersamulticenterretrospectivecohortstudy AT takumaokamura associationofprobioticusewithnivolumabeffectivenessagainstvariouscancersamulticenterretrospectivecohortstudy AT kenkeihasatani associationofprobioticusewithnivolumabeffectivenessagainstvariouscancersamulticenterretrospectivecohortstudy AT naohiroyoshida associationofprobioticusewithnivolumabeffectivenessagainstvariouscancersamulticenterretrospectivecohortstudy AT tsutomunishida associationofprobioticusewithnivolumabeffectivenessagainstvariouscancersamulticenterretrospectivecohortstudy AT tetsuyasumiyoshi associationofprobioticusewithnivolumabeffectivenessagainstvariouscancersamulticenterretrospectivecohortstudy AT shukiyotoki associationofprobioticusewithnivolumabeffectivenessagainstvariouscancersamulticenterretrospectivecohortstudy AT takashiikeya associationofprobioticusewithnivolumabeffectivenessagainstvariouscancersamulticenterretrospectivecohortstudy AT masahiroarai associationofprobioticusewithnivolumabeffectivenessagainstvariouscancersamulticenterretrospectivecohortstudy AT narikazuboku associationofprobioticusewithnivolumabeffectivenessagainstvariouscancersamulticenterretrospectivecohortstudy AT mitsuhirofujishiro associationofprobioticusewithnivolumabeffectivenessagainstvariouscancersamulticenterretrospectivecohortstudy |